Related Experiment Video
Updated: Jun 23, 2026
Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
Published on: June 28, 2019
Beta-arrestin-based Bret2 screening assay for the "non"-beta-arrestin binding CB1 receptor
Milka Vrecl1, Pia Karina Nørregaard, Dorthe L C Almholt
1Institute of Anatomy, Histology & Embryology, Veterinary Faculty, University of Ljubljana, Ljubljana, Slovenia. milka.vrecl@vf.uni-lj.si
Abstract:
CB1 receptor (CB1R) antagonists have been demonstrated to be effective in treating obesity and related disorders. This study has been focused on establishing a beta-arrestin 2-based screening assay for the CB1R using BRET2 technology. When the existing BRET2 screening platform was applied to the CB1R, the authors discovered that the receptor interacted weakly with beta-arrestin 2, resulting in unsatisfactory assay performance. To enhance the beta-arrestin binding capacity, they replaced the C-terminal tail of the CB1R with tails from either the V2 or BRS3 receptors, both of which interact strongly with beta-arrestin 2. Using this chimeric approach, the authors screened a small compound library and identified 21 antagonist and inverse agonist hits with IC50 and EC50 values ranging from 0.3 nM to 7.5 microM. Both primary and secondary screening were performed with Z'>0.5, suggesting that the assay is a robust and cost-effective alternative to existing cell-based assays.
Insights
Researchers developed a novel beta-arrestin 2 screening assay for the CB1 receptor (CB1R) to identify obesity treatments. By modifying the CB1R, they successfully screened compounds, finding 21 potent antagonists and inverse agonists.
Area of Science:
- Pharmacology
- Biochemistry
- Molecular Biology
Background:
- CB1 receptor (CB1R) antagonists show promise for treating obesity and related metabolic disorders.
- Existing screening assays for CB1R antagonists often face challenges with receptor-beta-arrestin interactions.
- Beta-arrestin 2 plays a crucial role in G protein-coupled receptor (GPCR) signaling and trafficking.
Purpose of the Study:
- To establish a robust and cost-effective beta-arrestin 2-based screening assay for the CB1 receptor using BRET2 technology.
- To enhance the interaction between CB1R and beta-arrestin 2 for improved assay performance.
- To identify novel CB1R antagonists and inverse agonists for potential therapeutic applications.
Main Methods:
- Utilized BRET2 (Bioluminescence Resonance Energy Transfer type 2) technology for developing the screening assay.
- Engineered chimeric CB1 receptors by replacing the C-terminal tail with those from V2 or BRS3 receptors to enhance beta-arrestin 2 binding.
- Screened a small compound library against the engineered CB1R-beta-arrestin 2 system.
Main Results:
- Identified 21 compounds exhibiting antagonist and inverse agonist activity against the CB1 receptor.
- Determined IC50 and EC50 values for the identified hits, ranging from 0.3 nM to 7.5 microM.
- Achieved robust assay performance with Z' values greater than 0.5 in both primary and secondary screening.
Conclusions:
- The developed chimeric CB1R-beta-arrestin 2 assay is a sensitive and reliable tool for identifying CB1R modulators.
- This assay offers a cost-effective and efficient alternative to existing cell-based screening methods for obesity drug discovery.
- The identified antagonists and inverse agonists represent potential therapeutic candidates for obesity and related conditions.
